Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions

Menigatti, M ; Staiano, T ; Manser, C N ; Bauerfeind, P ; Komljenovic, A ; Robinson, Mark D ; Jiricny, J ; Buffoli, F ; Marra, Giancarlo

Abstract: Epigenetic silencing of protein-encoding genes is common in early-stage colorectal tumorigenesis. Less is known about the methylation-mediated silencing of genes encoding microRNAs (miRNAs), which are also important epigenetic modulators of gene expression. Using quantitative PCR, we identified 56 miRNAs that were expressed in normal colorectal mucosa and in HT29 colorectal cancer cells treated with demethylating agents but not in untreated HT29 cells, suggesting that they probably undergo methylation-induced silencing during colorectal tumorigenesis. One of these, miR-195, had recently been reported to be underexpressed in colorectal cancers and to exert tumor-suppressor effects in colorectal cancer cells. We identified the transcription start site (TSS) for primary miRNA (pri-miR)-497/195, the primary precursor that yields miR-195 and another candidate on our list, miR-497, and a single CpG island upstream to the TSS, which controls expression of both miRNAs. Combined bisulfite restriction analysis and bisulfite genomic sequencing studies revealed monoallelic methylation of this island in normal colorectal mucosa (50/50 samples) and full methylation in most colorectal adenomas (38/50; 76%). The hypermethylated precancerous lesions displayed significantly downregulated expression of both miRNAs. Similar methylation patterns were observed at two known imprinted genes, MEG3 and GNAS-AS1, which encode several of the 56 miRNAs on our list. Imprinting at these loci was lost in over half the adenomas (62% at MEG3 and 52% at GNAS-AS1). Copy-number alterations at MEG3, GNAS-AS1 and pri-miR-497/195, which are frequent in colorectal cancers, were less common in adenomas and confined to tumors displaying differential methylation at the involved locus. Our data show that somatically acquired, epigenetic changes at monoallelically methylated regions encoding miRNAs are relatively frequent in sporadic colorectal adenomas and might contribute to the onset and progression of these tumors.

DOI: https://doi.org/10.1038/oncsis.2013.21

Originally published at:
Menigatti, M; Staiano, T; Manser, C N; Bauerfeind, P; Komljenovic, A; Robinson, Mark D; Jiricny, J; Buffoli, F; Marra, Giancarlo (2013). Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis, 2:e56. DOI: https://doi.org/10.1038/oncsis.2013.21
Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions

M Menigatti1, T Staiano2, CN Manser3, P Bauerfeind3, A Komljenovic4, M Robinson4, J Jiricny1, F Buffoli2 and G Marra1

Epigenetic silencing of protein-encoding genes is common in early-stage colorectal tumorigenesis. Less is known about the methylation-mediated silencing of genes encoding microRNAs (miRNAs), which are also important epigenetic modulators of gene expression. Using quantitative PCR, we identified 56 miRNAs that were expressed in normal colorectal mucosa and in HT29 colorectal cancer cells treated with demethylating agents but not in untreated HT29 cells, suggesting that they probably undergo methylation-induced silencing during colorectal tumorigenesis. One of these, miR-195, had recently been reported to be underexpressed in colorectal cancers and to exert tumor-suppressor effects in colorectal cancer cells. We identified the transcription start site (TSS) for primary miRNA (pri-miR)-497/195, the primary precursor that yields miR-195 and another candidate on our list, miR-497, and a single CpG island upstream to the TSS, which controls expression of both miRNAs. Combined bisulfite restriction analysis and bisulfite genomic sequencing studies revealed monoallelic methylation of this island in normal colorectal mucosa (50/50 samples) and full methylation in most colorectal adenomas (38/50; 76%). The hypermethylated precancerous lesions displayed significantly downregulated expression of both miRNAs. Similar methylation patterns were observed at two known imprinted genes, MEG3 and GNAS-AS1, which encode several of the 56 miRNAs on our list. Imprinting at these loci was lost in over half the adenomas (62% at MEG3 and 52% at GNAS-AS1). Copy-number alterations at MEG3, GNAS-AS1 and pri-miR-497/195, which are frequent in colorectal cancers, were less common in adenomas and confined to tumors displaying differential methylation at the involved locus. Our data show that somatically acquired, epigenetic changes at monoallelically methylated regions encoding miRNAs are relatively frequent in sporadic colorectal adenomas and might contribute to the onset and progression of these tumors.

Oncogenesis (2013) 2, e56; doi:10.1038/oncsis.2013.21; published online 15 July 2013

Subject Categories: Molecular oncology

Keywords: miR-497; miR-195; CpG-island methylation; allele-specific DNA methylation

INTRODUCTION

Discovered almost 30 years ago,1 cancer-related epigenetic alterations in gene expression patterns have now been found in almost every component of human chromatin.2 The most widely studied changes of this type involve DNA methylation at CpG dinucleotides, which can affect the expression of protein-coding genes and noncoding RNAs, such as microRNAs (miRNAs).3 The latter bind to messenger RNAs (mRNAs) with base-pair sequences more or less complementary to their own, causing degradation of the target transcript or repressing its translation.3 miRNAs are believed to regulate the translation of over 60% of all protein-coding genes,5 including many known oncogenes and tumor suppressors.8 Epigenetic silencing of protein-encoding genes is a well-documented feature of colorectal tumorigenesis,7–10 but less is known about the epigenetic regulation of miRNA genes in this setting.

We recently screened 742 human miRNAs to identify those whose expression in the colon might be silenced by DNA methylation during the course of malignant transformation. Unexpectedly, the candidates that emerged included several miRNA genes that were monoallelically methylated in normal colorectal mucosa, including some located in imprinted loci of the genome. The parent-of-origin-specific monoallelic expression that characterizes imprinting11 has crucial roles in normal growth and development.12 Genetic and/or epigenetic alterations can activate the normally silenced allele or silence the one that is normally expressed,13 and this loss of imprinting (LOI) has been described in several types of cancer.14 To date, ~80 imprinted human genes have been identified (http://www.geneimprint.com/), but bioinformatic predictions indicate that the true number is probably higher.11,15 Allele-specific DNA methylation (ASM) of nonimprinted genes also seems to be widespread in the human genome,16 and loci of this type are also potential targets of epigenetic changes relevant for tumorigenesis.

Here, we show that a single CpG island controls the expression of two miRNAs, miR-497 and miR-195, which appear to undergo silencing during colorectal tumorigenesis. In normal colorectal mucosa, this island was found to be monoallelically methylated, but in precancerous colorectal lesions, biallelic methylation was more common, a pattern similar to that observed at the CpG islands of two other multi-miRNA-encoding loci (MEG3 and GNAS-AS1), which are known to be imprinted.

RESULTS

Using quantitative real-time PCR (qPCR), we measured the levels of 742 human miRNAs in HT29 colorectal cancer cells before and
after treatment with the DNA-demethylating agent 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A and in a single sample of normal colonic mucosa. Fifty-six miRNA genes had expression patterns suggestive of methylation-induced silencing during colorectal tumorigenesis, that is, constitutive expression in normal mucosa, loss of expression in HT29 cells and restored expression in HT29 cells treated with 5-aza-2-deoxycytidine/trichostatin A (Table 1, left column).

Shortly after we completed these experiments, one of the candidate miRNAs, miR-195, was reported to be underexpressed in colorectal cancers (73% of the 81 carcinomas analyzed) and to exert tumor-suppressor activity in HT29 and LoVo colon cancer cells involving the reduction of BCL2 levels. These findings, along with reports of miR-195-induced tumor suppression in hepatocellular, adrenocortical, and peritoneal tumor models, prompted us to explore a CpG island flanking this site as a potential target of miRNA cluster transcription.

Given the criteria used in our screening study, the most likely cause seemed to be cytosine methylation at CpG island(s) in the miR-195 promoter region. MiR-195 and miR-497, another miRNA gene that appeared to be epigenetically silenced during colorectal-cell transformation (Table 1), are both encoded in the gene that appeared to be epigenetically silenced during colorectal tumorigenesis. During colorectal tumorigenesis, both of these miRNAs were found in the hypermethylated tumors of both normal mucosa samples: GNAS-AS1, M Menigatti et al. 2013 Macmillan Publishers Limited.
MEG3, which encodes 16 miRNAs in our list.27,28 The results recalled those obtained for pri-miR-497/195 CpG island. Methylated and unmethylated alleles of GNAS-AS1 and MEG3 were found in all 50 specimens of normal mucosa, whereas methylated alleles of both loci predominated in most adenomas (Figures 3a and b), reflecting tumor-related LOI. Twenty-six (52%) of the 50 adenomas presented LOI at GNAS-AS1 (involving hypermethylation of the active allele in 24 and hypomethylation of the silenced allele in 2). LOI at MEG3 was even more common: hypermethylation of this locus was documented in 31 (62%) of the adenomas.

RT–PCR confirmed that miR-296-5p expression was significantly downregulated in adenomas with LOI at GNAS-AS1 (Figure 3a). For the MEG3 locus, which encodes over 50 miRNAs,29 we limited our analysis to three of those that appeared to undergo epigenetic silencing during colorectal tumorigenesis (Table 1). As shown in Figure 3b, two of these, miR-127-3p and miR-154, displayed underexpression (statistically significant in the latter case) in the adenomas with LOI at MEG3, whereas the third, miR-495, was slightly but not significantly overexpressed in these tumors.

Collectively, these data suggest that pri-miR-497/195 is—like GNAS-AS1 and MEG3—an imprinted locus, and that imprinting at all three loci is frequently lost during colorectal tumorigenesis. As shown in Figure 4, 20 (40%) of the 50 adenomas we examined exhibited hypermethylation at all three loci, and 12 others (24%) were methylated at two of the three. Only seven adenomas (14%) exhibited methylation at all three loci that was similar to that of their paired samples of normal mucosa.

LOI can also stem—wholly or in part—from genetic events, such as copy-number alterations (CNAs). Using qPCR, we assessed CNA frequencies at GNAS-AS1 (chromosome 20q13.3), MEG3 (14q32) and pri-miR-497/195 (17p13.1) in our 50 adenomas. As reported in Figure 4, nine of the tumors presented amplifications, which involved GNAS-AS1 in seven tumors, pri-miR-497/195 in one and MEG3 in another. Deletions were found at pri-miR-497/195 in four adenomas and at MEG3 in one. Interestingly, all the CNAs were found in adenomas with COBRA-documented differential methylation of the involved locus (compared with normal mucosa from the same patient), including the two that appeared to be hypomethylated at the GNAS-AS1 locus.

**Figure 1.** Identification of the pri-miR-497/195 TSS in normal human colorectal mucosa and assessment of the methylation status of the CpG island located upstream from this site. (a) 5' RACE: a 3638-bp product was obtained by nested PCR with the gene-specific outer and inner primers listed in Material and methods. (b) Schematic showing locations of miR-497 and miR-195, the pri-miR-497/195 TSS and the CpG island located upstream from the latter (genome coordinates of pri-miR-497/195 from its TSS to miR-497 according to the Human Reference Sequence GRCh37/hg19: chr17, 6 921 342–6 924 948). The position of the 294-bp COBRA amplicon is 6 926 487–6 926 780. (c) COBRA analysis of six colorectal cancer cell lines and a control sample of normal colon mucosa. Arrows indicate TaqI-digested DNA fragments representing methylated alleles; slower-migrating fragments represent undigested, unmethylated DNA. (d) COBRA revealed methylated and unmethylated pri-miR-497/195 alleles in isolated epithelial cells and isolated stromal (lamina propria) cells from the normal mucosa. (e) Left panel: the purity of the epithelial cell preparation was confirmed by qPCR exclusion of the expression of Vimentin, a stromal marker that was abundant in the lamina propria specimens. Right panel: RT–PCR revealed higher expression of miR-195 and miR-497 in the stromal component.
This is the first evidence suggesting that the pri-miR-497/195 locus might be imprinted in colorectal tissues. To validate this hypothesis in our colorectal tissue samples, we analyzed the transcribed pri-miR-497/195 sequence identified by 5’ RACE for single-nucleotide polymorphisms (SNPs) that could be employed to distinguish alleles. Unfortunately, the only candidate that emerged, SNP rs412999 (dbSNP ID: 412999), is extremely rare in individuals of northern and western European ancestry (CEU samples of The HapMap 3 collection) and was therefore unsuitable for use in our tissue series. As an alternative, we sequenced RNA from B-lymphocytes from three Nigerian individuals known to be heterozygous for this SNP, but as shown in Supplementary Table 1, none of the samples exhibited any evidence of preferential allelic expression.

Our final set of experiments focused on putative or validated mRNA targets of miR-497 and miR-195 identified in public databases (mirTarBase, miRecords and miRWalk). In a data set previously collected by our group, 33–35 of these mRNAs had presented significantly upregulated expression in precancerous colorectal lesions (relative to normal mucosa samples from Table 2. Characteristics of the 50 patients with precancerous colorectal lesions included in the study

| Patient no. | Sex | Age | Colon segment involveda | Maximum lesion diameter (mm) | Macroscopic appearanceb | Pit patternc | Microscopic appearance | Dysplasia4 | No. of lesions presentd |
|-------------|-----|-----|-------------------------|-------------------------------|-------------------------|-------------|-------------------------|-----------|-------------------------|
| 1           | F   | 75  | Tra                     | 20                           | IIa                     | IIIS-IIIL   | VA                      | High      | 7                       |
| 2           | F   | 75  | Tra                     | 40                           | IIa-Ilc                 | IIIS-IIIL   | TA                      | High      | 1                       |
| 3           | F   | 54  | Cec                     | 45                           | III                    | III         | IV                      | Low       | 16                      |
| 4           | M   | 73  | Asc                     | 30                           | Is                     | nr          | TVA                     | High      | 1                       |
| 5           | F   | 69  | Asc                     | 45                           | Ip                     | nr          | TVA                     | High      | 1                       |
| 6           | M   | 74  | Rec                     | 40                           | Is                     | IV          | VA                      | high      | 2                       |
| 7           | M   | 80  | Asc                     | 40                           | IIa                    | IIIL        | TVA                     | Low       | 1                       |
| 8           | M   | 77  | Cec                     | 25                           | IIa                    | III         | TVA                     | Low       | 1                       |
| 9           | M   | 71  | Sig                     | 30                           | IIa                    | III         | TVA                     | Low       | 2                       |
| 10          | M   | 89  | Rec                     | 30                           | Is                     | IV          | TA                      | Low       | 3                       |
| 11          | F   | 85  | Sig                     | 25                           | Is-IIa                 | IV          | TA                      | Low       | 1                       |
| 12          | F   | 63  | Sig                     | 35                           | Ip                     | IV          | VA                      | Low       | 1                       |
| 13          | M   | 82  | Asc                     | 15                           | IIa                    | IIIL        | VA                      | Low       | 2                       |
| 14          | F   | 73  | Asc                     | 25                           | IIa-Iii                 | III-IIIIL   | TA                      | Low       | 1                       |
| 15          | F   | 70  | Cec                     | 25                           | IIa                    | III         | TVA                     | Low       | 2                       |
| 16          | M   | 70  | Asc                     | 15                           | Is                     | IV          | TVA                     | Low       | 7                       |
| 17          | M   | 63  | Asc                     | 45                           | Is                     | III-IV      | TVA                     | Low       | 1                       |
| 18          | F   | 73  | Sig                     | 20                           | Ip                     | IV          | TVA                     | Low       | 1                       |
| 19          | M   | 60  | Des                     | 30                           | Is                     | IV-Vi       | TVA                     | High      | 1                       |
| 20          | M   | 68  | Asc                     | 30                           | Is-IIa                 | III-IV      | TVA                     | Low       | 1                       |
| 21          | M   | 55  | Cec                     | 25                           | Is-IIa                 | III-IV      | SSA                     | Low       | 1                       |
| 22          | M   | 64  | Sig                     | 12                           | Ip                     | III         | TA                      | Low       | 1                       |
| 23          | M   | 78  | Asc                     | 50                           | Is                     | IV-Vi       | TA                      | Low       | 1                       |
| 24          | F   | 69  | Rec                     | 90                           | Is-IIa                 | IV          | TVA                     | Low       | 1                       |
| 25          | F   | 78  | Rec                     | 60                           | Is-IIa                 | IV          | TVA                     | Low       | 1                       |
| 26          | M   | 72  | Asc                     | 30                           | Is                     | IV          | TVA                     | Low       | 2                       |
| 27          | M   | 76  | Sig                     | 30                           | Is                     | IV-Vi       | TA                      | High      | 1                       |
| 28          | M   | 75  | Rec                     | 25                           | Is                     | IV-Vn       | TVA                     | High      | 6                       |
| 29          | M   | 66  | Asc                     | 30                           | IIa                    | III         | TA                      | High      | 2                       |
| 30          | F   | 66  | Asc                     | 30                           | Is-IIa                 | IV          | TA                      | High      | 2                       |
| 31          | M   | 75  | Tra                     | 18                           | IIa                    | IIIL        | TVA                     | Low       | 1                       |
| 32          | M   | 61  | Asc                     | 40                           | Is-IIa                 | IV          | TVA                     | Low       | 20                      |
| 33          | M   | 84  | Cec                     | 30                           | Is                     | Vn          | TVA                     | High      | 1                       |
| 34          | M   | 59  | Tra                     | 30                           | IIa-Iii                 | III-IIIIL   | TA                      | Low       | 1                       |
| 35          | F   | 73  | Rec                     | 50                           | Is                     | IV          | TVA                     | Low       | 1                       |
| 36          | F   | 73  | Des                     | 25                           | Is                     | IV          | TA                      | Low       | 1                       |
| 37          | M   | 59  | Rec                     | 60                           | Is                     | IV-Vi       | TVA                     | High      | 1                       |
| 38          | M   | 75  | Asc                     | 40                           | IIa                    | II          | TVA                     | Low       | 6                       |
| 39          | M   | 75  | Asc                     | 50                           | Is                     | Vn          | TVA                     | High      | 7                       |
| 40          | M   | 77  | Sig                     | 25                           | IIa-Iii                 | III-IIIIL   | TA                      | Low       | 1                       |
| 41          | F   | 72  | Asc                     | 20                           | Is                     | IV          | TVA                     | Low       | 1                       |
| 42          | F   | 66  | Sig                     | 35                           | Ip                     | IV          | TA                      | Low       | 1                       |
| 43          | F   | 78  | Rec                     | 45                           | Ip                     | IV          | TVA                     | High      | 1                       |
| 44          | M   | 74  | Sig                     | 25                           | Ip                     | III-IV      | TA                      | Low       | 1                       |
| 45          | M   | 60  | Cec                     | 30                           | Is                     | IV          | TVA                     | Low       | 2                       |
| 46          | M   | 62  | Des                     | 22                           | Ip                     | nr          | TVA                     | Low       | 1                       |
| 47          | F   | 68  | Asc                     | 16                           | IIa                    | nr          | TA                      | High      | 1                       |
| 48          | F   | 46  | Des                     | 30                           | Ip                     | nr          | TVA                     | High      | 2                       |
| 49          | M   | 75  | Cec                     | 20                           | Is                     | nr          | TVA                     | Low       | 1                       |
| 50          | M   | 59  | Sig                     | 8                            | Ip                     | nr          | TA                      | Low       | 2                       |

*Abbreviations: Asc, ascending colon; Cec, cecum; Des, descending colon; nr, pit pattern not reported by the endoscopist; Rec, rectum; Sig, sigma; SSA, sessile serrated adenoma; TA, tubular adenoma; Tra, transversum; TVA, tubulovillous adenoma; VA, villous adenoma. aClassified according to the Paris Endoscopic Classification of Superficial Neoplastic Lesions.60 bKudo classification of colonic crypt morphology.61 cHighest degree of dysplasia in the lesion based on the WHO classification of tumors of the digestive system.62 dTotal number of lesions noted during the study colonoscopy, including those used in the present study.
Our attempt to identify miRNAs whose expression is epigenetically downregulated in colorectal adenomas revealed that changes of this type were surprisingly frequent in miRNA-cluster loci that were monoallelically methylated in normal colorectal mucosa. We investigated the methylation statuses of CpG islands located upstream from the TSSs of three of these loci (MEG3, GNAS-AS1 and pri-miR-497-195) in 50 paired samples of colorectal adenoma-normal mucosa. All three displayed biallelic methylation in a high percentage of the tumors.

For MEG3 and GNAS-AS1, which are imprinted loci, this tumor-related hypermethylation of the CpG islands that control their transcription results in LOI. The link between this phenomenon and cancer was first noted in 1993, when two laboratories independently reported biallelic expression of the imprinted gene IGF2 in Wilms tumors. Later, IGF2 LOI was also found in normal and lesional tissues from patients with colorectal cancer, and subsequent studies pointed to hypomethylation-mediated activation of the normally silent, maternally inherited IGF2 allele as a risk factor for familial forms of colorectal cancer. Interestingly, an miRNA gene embedded within IGF2, miR-483, also appears to be frequently overexpressed in different human cancers, including those of the colon. Thus far, KCNQ1OT1 is the only other gene known to undergo LOI in colorectal cancers, but its expression in the precancerous phase of colon tumorigenesis has not been characterized.

The high frequency of LOI at the MEG3 and GNAS-AS1 miRNA-cluster loci in colorectal adenomas has never been reported, but LOI at MEG3 has been associated with hematologic malignancies, meningiomas and pituitary adenomas. Hypermethylation of the CpG island at MEG3 leading to LOI was
Figure 3. Methylation analysis of regions of GNAS-AS1 (a) and MEG3 (b) that are differentially methylated in adenomas and normal mucosal samples. Both panels include schematic depictions of the imprinted locus (upper left); examples of COBRA (lower left) and BGS results (upper right); and expression levels for miRNAs encoded in the locus measured in adenomas in which the locus was hypermethylated or normally methylated. (Each panel includes representative COBRA results for two adenomas with hypermethylation at the locus and one normally methylated adenoma.) (a) MiR-296-5p expression was significantly downregulated ($P = 0.0080$) in adenomas with hypermethylation of the GNAS-AS1 CpG island. (b) Adenomas whose MEG3 CpG island was hypermethylated displayed significantly downregulated miR-154 expression ($P = 0.0183$) and substantial but nonsignificant downregulation of miR-127-3p expression ($P = 0.0717$). ad, adenoma; nm, normal mucosa.

Figure 4. Epigenetic and genetic variations at the three loci investigated in our 50 adenomas. For each locus, the upper row of squares shows the methylation status of each tumor (black, hypermethylation; gray, normal methylation; white, hypomethylation), and the lower row indicates the CNA status (A, amplification; D, deletion; red, loss of the active (unmethylated) allele; green, gain in the number of active (unmethylated) alleles; white, no CNA).
detected in over 60% of our colorectal adenomas. However, the transcriptional regulation of this locus is highly complex (Figure 3b). Discordance between MEG3 expression and the expression of certain miRNAs included in this locus has been reported in pituitary adenomas,45 and a similar picture emerged in the colorectal adenomas we analyzed. In tumors with LOI at MEG3, miR-154 and miR-127-3p expression was clearly downregulated (P = 0.01 and P = 0.07, respectively) but miR-495 expression was not. MEG3 encodes over 50 miRNAs,46 so extensive transcriptional analysis will be necessary to delineate the consequences of epigenetic alterations at this locus in colorectal adenomas.

Over half of our adenomas displayed LOI at the GNAS-AS1 locus on chromosome 20q13.3.46 GNAS-AS1 contains imprinted protein-coding genes and antisense transcripts. Two miRNA genes included in this locus, miR-296 and miR-298, has also been recently confirmed.47 Underexpression of miR-296 has been documented in various types of cancers,48,49 including metastatic lesions from colorectal malignancies,50 but its cause has not been explored. Our findings indicate that the reduced expression association with human colorectal tumorigenesis may well be due to miR-296 LOI, which appears to be a frequent, early event in this process that generally stems from epigenetic alterations (Figure 4).

As for the third gene cluster we tested, miR-497/miR-195 is on chromosome band 17p13.1, its imprinting status is unknown. We identified the pri-miR-497/195 TSS and found that the CpG island located upstream from this site is monoallelically methylated in the normal colon mucosa. In contrast, the island was hypermethylated in roughly 75% of the colorectal adenomas we tested (Figure 4), and this change was associated with significant downregulated expression of both miR-497 and miR-195 (Figure 2c).

This methylation pattern and its similarity to those of GNAS-AS1 and MEG3 (Figure 3) suggest that the pri-miR-497/195 locus might be a novel imprinted region of the genome. This hypothesis would have been strengthened by findings of preferential allelic expression in the lymphoblast cell DNA we analyzed, but it cannot be rejected solely on the basis of the absence of such evidence. Indeed, pri-miR-497/195 imprinting might simply be a tissue-specific phenomenon that occurs in colorectal cells (and possibly other cells as well) but not in lymphocytes.51 Interestingly, a review of the COBRA and bisulfite genomic sequencing (BGS) data published recently reveals that this locus also tends to be monoallelically methylated in normal human breast tissues and hypermethylated in breast cancers. An alternative hypothesis is that the phenomenon we observed at pri-miR-497/195 represents ASM of a nonimprinted locus,16 but this seems less likely for two reasons: (1) Nonimprinted ASM is usually an individual-specific phenomenon,16 whereas ASM at pri-miR-497/195 was observed in all 50 of the normal colorectal mucosal samples we examined; and (2) the pri-miR-497/195 ASM involves a canonical CpG island—a typical feature of bona fide imprinting—whereas nonimprinted ASM generally affects other DNA sequences.53

Regardless of whether it is imprinted or not, the fact that pri-miR-497/195 is monoallelically methylated in normal colorectal mucosa and biallelically methylated in most preinvasive tumors of this tissue is potentially important in terms of the development and clinical outcome of colorectal cancer. Guo et al.44 showed that miR-497 exerts tumor-suppressor activity in colorectal cancer by downregulating the expression of insulin-like growth factor 1. Downregulation of miR-195 expression has been significantly linked to increased mortality in patients with this type of cancer.55 Furthermore, Liu et al.17 found that this miRNA is frequently underexpressed in colorectal cancers (73% of those they examined) and that it exerts tumor-suppressor effects in colon cancer cell lines, which are mediated by downregulation of BCL2 expression. The fact that BCL2 mRNA levels were not increased in the adenomas of our series that exhibited pri-miR-497/195 hypermethylation might reflect differences between the dynamics of miRNA/target regulation in tissues and those observed in cell lines, as suggested by our preliminary data on BCL2 protein expression (Supplementary Figure 2). This finding, however, together with the lack of negative correlation between transcript levels of pri-miR-497/195 and those of four other possible miR-497/195 targets (Supplementary Figure 1), also suggests that the regulatory effects of pri-miR-497/195 may be exerted mainly during mRNA translation.

Underexpression of miR-497 and miR-195 was also associated with DNA copy-number reductions in 93 (71%) of the 131 colorectal cancers analyzed by Guo et al.,44 suggesting that genetic alterations at this locus of chromosome 17p13.1 are common in advanced-stage colorectal malignancies. These findings are consistent with our own, which suggest that epigenetic alterations may precede CNAs at this locus. Hypermethylation at 17p13.1 was observed in roughly 75% of our adenomas, but only 10% of these tumors exhibited CNAs. In contrast, CNAs at this locus were detected in 24.3% of the 833 colorectal cancers included in the Progenetix database.56 The Progenetix tumors were also frequently characterized by CNAs at MEG3 (16.4%) and GNAS-A1 (48.1%). These patterns suggest that early epigenetic alterations might ‘prime’ certain regions for subsequent loss or gain of genetic material, which—depending on the genes affected—could have important implications for tumorigenesis (for example, deletion of the tumor-suppressor gene TP53, which is located close to miR-497/miR-195 on chromosome 17p13.1). In conclusion, our findings reopen the debate on the importance of LOI in the early stages of colorectal tumorigenesis. Sporadic colorectal adenomas seem to be characterized by a relatively high frequency of epigenetic alterations affecting miRNA-cluster loci that are monoallelically methylated in normal mucosa, and some of these are known to be imprinted. Somatically acquired changes of this type could drive transformation by directly affecting gene expression, but there is also reason to suspect that they predispose neoplastic cells to genomic alterations. Additional work is needed to determine whether pri-miR-497/195 is also, as we suspect, an imprinted locus and to clarify its miRNA targets.

MATERIALS AND METHODS

Cell lines and tissue samples

Colorectal cancer cell lines (HT29, SW48, GPDS, LS174T, SW620, Colo741, SW480, HCT116 and SW837) were obtained from the Zurich Cancer Network’s Cell Line Repository. Cells from this repository have undergone approval from patients undergoing colonoscopy in Cremona, Italy (Istituti Ospitalieri) or Zurich, Switzerland (University Hospital). They were used in accordance with the Declaration of Helsinki, and each donor provided written informed consent to sample collection, analysis of data and publication of the findings. We obtained 50 precancerous lesions (adenomas), each with a paired sample of normal mucosa from the same colon segment, >2 cm from the lesion. As these tissues were collected endoscopically, they were relatively superficial samples with consistently high epithelial contents.

Comparative studies of the epithelial and stromal components of the mucosa were carried out on a single, freshly excised specimen of normal colon from a patient undergoing surgery for diverticulitis. (This donor provided written informed consent, as described above for patients with adenomas.) Epithelial crypts and lamina propria were isolated from this specimen as previously described.57

Genomic DNA and total RNA (including small RNAs) were purified with commercially available kits. In brief, samples were lysed and homogenized in RTL Plus Buffer (Qiagen, Basel, Switzerland). The DNA was purified on spin columns (AllPrep DNA/RNA Mini Kit, Qiagen), and the total RNA was purified from the AllPrep column flow-through with Mini Spin Columns (miRCURY RNA Isolation Kit, Exiqon, Vedbaek, Denmark).
DNA demethylation

HT29 cells were subjected to DNA demethylation treatment the day after seeding. Cells were grown in medium containing 5-aza-2-deoxycytidine (Sigma, Buchs SG, Switzerland), which was renewed every 24 h. After 72 h, they were transferred to medium containing trichostatin A (final concentration 300 nM) (Sigma) for an additional 16-h growth.

miRNA profiling

miRNA levels were measured in HT29 cells, before and after demethylation, and in normal colorectal mucosa. We used Exiqon’s MicroRNA Ready-to-Use PCR, Human panel I – II, V2.R, which includes assays for 742 mature miRNAs and 6 reference genes. The reverse-transcribed RNA (obtained with the miRCURY LNA Universal RT microRNA PCR, Polyadenylation and cDNA Synthesis kit from Exiqon) was added to the PCR panels with SYBR Green Master Mix (Exiqon), and real-time PCR was performed with a Roche Lightcycler 480 system (Roche, Rotkreuz, Switzerland). miRNAs with a Cq of >40 were classified as nonexpressed. Supplementary Table 3 shows the LNA PCR primer sets used to quantify individual miRNAs.

5’ RACE

To identify the TSS for pri-miR-497/195, we used 5’ RACE (Ambion’s FirstChoice RLM-RACE Kit, Ambion, Zug, Switzerland) to analyze 10 μg of total RNA from normal human colonic mucosa. Two specific primers (Supplementary Table 3) were designed to perform nested-PCR amplification of Homo sapiens cDNA FLJ25640 fs, clone STM04823 (GeneBank Accession AK098506) encompassing the mature forms of mir-497 and miR-195 (miRBase 19). The miR-RACE amplicon was then cloned (InstaClone PCR Cloning kit, Fermentas, St Leon-Rot, Germany) and its specificity confirmed by sequencing.

Bisulfite conversion, COBRA and BGS

Sodium bisulfite conversion of genomic DNA was done with Qiagen’s Epitect Bisulfite kit. COBRA was performed as previously described.84 (See Supplementary Table 3 for primer sequences and PCR conditions.) Amplicons were digested with BstUI (GNAS-AS1 and MEG3 Cpg islands) and TaqI (pri-miR-497/195 5’ Cpg island) restriction enzymes (New England Biolabs, Beverly, MA, USA). For BGS, PCR products were cloned with the InstaClone PCR Cloning kit (Fermentas), and individual clones were sequenced.

qPCR copy-number analysis

Copy numbers at the pri-miR-497/195, MEG3 and GNAS-AS1 loci were determined with predesigned assays (SABiosciences, Frederick, MD, USA) and qBiomarker SYBR Green qPCR Mastermix (Qiagen). Gene copy numbers were averaged with the ΔΔCT method after PCR efficiency correction.58 The Human Multiplex Reference PCR Assay (SABiosciences, Assay ID: VPH000-00000000A) was used to normalize input DNA. (Locus-specific assay IDs are listed in Supplementary Table 3.) Pooled DNA from three samples of normal colonic mucosa was used as the calibrator, and assay specificity was validated on DNAs from colon cancer cell lines (HT29, SW480, SW587, HCT116 and SW48) with known genome-wide copy-number alteration profiles.59 Loci were classified as amplified or deleted when their estimated copy numbers were >2.5 or <1.5, respectively.

Analysis of pri-miR-497/195 allelic expression in human white blood cells

Three lymphoblast cell lines were obtained from the Coriell Institute for Medical Research. Each line came from a member of the Yoruba population in Ibadan, Nigeria, who was heterozygous for the SNP rs412999 (dbSNP ID: 412999) in the pri-miR-497/195 locus. Individual subcloned PCR products from retrotranscribed RNA isolated from these cells were sequenced to assess differential allelic expression of pri-miR-497/195. Primers used for genotyping are listed in Supplementary Table 3.

Quantitative real-time reverse-transcription PCR

First-strand cDNA synthesis, qPCR and relative quantification of transcript levels were performed as previously described.85 All primer sequences are reported in Supplementary Table 3.

BCL2 immunohistochemistry

Immunostaining was performed with BCL2 antibody (no. 790-4464; Ventana, Tucson, AZ, USA) as described elsewhere.7

Statistical analysis

Two-tailed P-values were calculated with the unpaired t-test to compare differences between sample miRNA and mRNA expression means. Analyses were performed using the GraphPad Prism 5.0 statistical software package for Macintosh computers (GraphPad, La Jolla, CA, USA).

ACKNOWLEDGEMENTS

We thank Dr Nitin Kumar for productive discussion, and Ritra Haider, Mirjam Schneider and Anuli Uzozie for technical assistance. The research was supported by grants from the Swiss Cancer League (KFS-02739-02-2011) and the University Research Priority Program Systems Biology/Functional Genomics (University of Zurich).

REFERENCES

[1] Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89–92.
[2] Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683–692.
[3] Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 2012; 31: 1609–1622.
[4] Iorio MV, Croce CM. MicroRNA involvement in human cancer. Carcinogenesis 2012; 33: 1126–1133.
[5] Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian miRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92–105.
[6] Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology 2012.
[7] Menigatti M, Truninger K, Gebbers JO, Marbet U, Marra G, Schär P. Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the MLH1 and MGMT promoters. Oncogene 2009; 28: 899–909.
[8] Menigatti M, Cattaneo E, Sabates-Bellar E, Jinsky WV, West P, Buffoli F et al. Protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. Mol Cancer 2009; 8: 124.
[9] Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4A) methylation and p53 mutation status. Cancer Res 2000; 60: 129–133.
[10] Suzuki H, Gabrielson E, Chen WH, Anbazhagan R, van Engeland M, Weienberg MP et al. A genomic screen for genes upregulated by demethylation and histone deacetylation inhibition in human colorectal cancer. Nat Genet 2002; 31: 141–149.
[11] Sha K. A mechanistic view of genomic imprinting. Ann Rev Genomics Hum Genet 2008; 9: 197–216.
[12] Das R, Hampton DD, Jirtle RL. Imprinting evolution and human health. Mamm Genome 2009; 20: 563–572.
[13] Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor of human cancer. Nat Rev Genet 2006; 7: 21–33.
[14] Uribe-Lewis S, Woodfine K, Stojic L, Murrell A. Molecular mechanisms of genomic imprinting and clinical implications for cancer. Expert Rev Mol Med 2011; 13: e2.
[15] Luelli PP, Dietrich FS, Weidman JR, Bosko JM, Jirtle RL, Hartemink AJ. Computational and experimental identification of novel human imprinted genes. Genome Res 2007; 17: 1273–1270.
[16] Tycko B. Allele-specific DNA methylation: beyond imprinting. Hum Mol Genet 2010; 19: R201–R220.
[17] Liu L, Chen L, Xu Y, Li R, Du X. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 2010; 400: 236–240.
[18] Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113–121.
[19] Furuta M, Kozaki KI, Tanimoto K, Tanaka S, Arii S, Shimamura T et al. The tumor-suppressive cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. Mol Cancer 2013; 12: e60155.
[20] Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak JS, Campbell PR et al. MiR-195 and miR-483-5p identified as predictors of poor prognosis in adenocarcinoma. Clin Cancer Res 2009; 15: 7684–7692.
[21] Flavin RJ, Smyth PC, Laios A, O'Toole SA, Barrett C, Finn SP et al. Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Mod Pathol 2009; 22: 197–205.
[22] Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008; 22: 3172–3183.
[23] Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kamiński N, Benos PV. Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 2009; 4: e5279.
Silencing of miRNA clusters in colorectal adenomas
M Menigatti et al

24 Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012; 31: 2062–2074.

25 Liu J, Nealon JG, Weinstein LS. Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 2005; 14: 95–102.

26 Robson JE, Eaton SA, Underhill P, Williams D, Peters J. MicroRNAs 296 and 298 are imprinted and part of the GNAS/Gnas cluster and miR-296 targets IKKBE and Tmed9. RNA 2012; 18: 135–144.

27 Murphy SK, Wylie AA, Coveler KJ, Cotter PD, Papenhausen PR, Sutton VR et al. Epigenetic detection of human chromosome 14 uniparental disomy. Hum Mutat 2003; 22: 92–97.

28 Kagami M, O’Sullivan MJ, Green AJ, Watabe Y, Ariyaka O, Masawa N et al. The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet 2010; 6: e1000992.

29 Kircher M, Bock C, Paulsen M. Structural conservation versus functional divergence of maternally expressed microRNAs in the Dlk1/Gtl2 imprinting region. BMC Genomics 2008; 9: 346.

30 Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011; 39: D163–D169.

31 Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37: D105–D110.

32 Dweep H, Stich C, Pandey P, Gretz N. miRNAWalk-database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011; 44: 839–847.

33 Cattaneo E, Laczkó E, Buffolì F, Zorzi F, Bianco MA, Menigatti M et al. Preimvasive colorectal lesion transcriptomes correlate with endoscopic morphology (polypoid vs. nonpolypoid). EMBO Mol Med 2011; 3: 334–347.

34 Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human tissue. Nature 1993; 362: 747–749.

35 Ogawa O, Eccles MR, Szeto J, McNee LA, Yun K, Maw MA et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature 1993; 362: 749–751.

36 Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998; 4: 1276–1280.

37 Cui H, Cruz-Correa M, Giardiello FM, Hutchison DF, Kafonok DR, Brandenburg S et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753–1755.

38 Cui H, Ohnysango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGFL2. Cancer Res 2002; 62: 6442–6446.

39 Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Foroni F et al. Oncogenic role of miR-483-3p at the IGF2/IGF3 locus. Cancer Res 2010; 70: 3140–3149.

40 Cancer Genome Atlas Network. Comprehensive molecular characterization of colorectal adenocarcinoma. Nature 2012; 487: 330–337.

41 Hao J, Zhang S, Zhou Y, Hu X, Shao C. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett 2011; 585: 207–213.

42 Nakano S, Murakami K, Meguro M, Soejima H, Higashimoto K, Urano T et al. Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer Sci 2006; 97: 1147–1154.

43 Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsira S, Syrrou M et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010; 34: 148–153.

44 Zhang X, Gejman R, Mahta A, Zhong Y, Rice KA, Zhou Y et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 2010; 70: 2350–2358.

45 Cheunuschon P, Zhou Y, Zhang X, Lee H, Chen W, Nakayama Y et al. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am J Pathol 2011; 179: 2120–2130.

46 Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci USA 1998; 95: 10038–10043.

47 Hayward BE, Bontron DT: An imprinted antisense transcript at the human GNAS1 locus. Hum Mol Genet 2000; 9: 835–841.

48 Wei JJ, Wu X, Peng Y, Shi G, Basturk O, Yang X et al. Regulation of HMG1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 2011; 17: 1297–1305.

49 Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 2012; 18: 981–992.

50 Vaira V, Faversani A, Dohi T, Montorsi M, Augello C, Gatti S et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 2012; 31: 27–38.

51 Prickett AR, Oakey RJ. A survey of tissue-specific genomic imprinting in mammals. Mol Genet Genomics 2012; 287: 621–630.

52 Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17: 1722–1730.

53 Zhang Y, Rohde C, Reinhardt R, Voelcker-Rehage C, Jeltsch A. Non-imprinted allele-specific DNA methylation on human autosomes. Genome Biol 2009; 10: R138.

54 Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY et al. MicroRNA-497 targets insulin-like growth factor I receptor and has a tumour suppressive role in human colorectal cancer. Oncogene 2013; 32: 1910–1920.

55 Wang X, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 2012; 29: 919–927.

56 Baudis M, Cleary ML. Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001; 17: 1228–1229.

57 Fujimoto K, Beauchamp RD, Whitehead RH. Identification and isolation of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2000; 85: 207–213.

58 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 2001; 29: 440–448.

Oncogenesis: An open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/